A. Luque
Sofia University
12 Papers
26 Citations
A. Luque is an academic researcher from Sofia University. The author has contributed to research in topics: Liver transplantation & Medicine. The author has an hindex of 6, co-authored 12 publications.
Chat about Author
Papers
A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection.
Javier Briceño,Álvaro Naranjo,Ruben Ciria,Rafael Díaz-Nieto,J.M. Sánchez-Hidalgo,A. Luque,S. Rufian,Pedro López-Cillero +7 more
TL;DR: The use of a new carrier-bound collagen sponge after major liver resection may be recommended because of its clinical and cost-savings effectiveness.
81
Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
Ruben Ciria,P. López-Cillero,A.-B. Gallardo,J. Cabrera,M. Pleguezuelo,María Dolores Ayllón,A. Luque,L. Zurera,J.-J. Espejo,Manuel Rodríguez-Perálvarez,J.L. Montero,M. de la Mata,Javier Briceño +12 more
TL;DR: Management of Intermediate BCLC-B HCC stage should be more complex and include updated criteria regarding B-stage subclassifications, VI and tumour differentiation, as well as modern surgical resection would offer improved survival benefit with acceptable safety in selected BCLB-B stage patients.
75
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant.
Patricia Aguilar-Melero,A. Luque,María del Mar Granados Machuca,María P. Pérez de Obanos,Rocío Navarrete,Inés C. Rodríguez-García,Javier Briceño,Maria Iñiguez,Juan Carlos Ruiz,Jesús Prieto,Manuel de la Mata,Rafael J. Gómez-Villamandos,Jordi Muntané,Pedro López-Cillero +13 more
TL;DR: The first report to show that the administration of CT-1 to donors would benefit the outcome of OLT is shown, and beneficial effects related to the activation of AKT, ERK, and STAT3, reduced caspase-3 activity and diminished IL-1β and TNF-α expression together with IL-6 upregulation in liver tissue are shown.
34
Contribution of Marginal Donors to Liver Transplantation for Hepatitis C Virus Infection
Javier Briceño,Ruben Ciria,M. Pleguezuelo,Álvaro Naranjo,J.M. Sánchez-Hidalgo,Juan Ruiz-Rabelo,P. López-Cillero,A. Luque,M. de la Mata,S. Rufian +9 more
- 01 Sep 2007
TL;DR: Among HCV recipients, marginal liver donors worked similar to those from "good" donors, except for those with fatty livers >30%, especially when combined with a prolonged cold ischemia time.
33
Model for End-stage Liver Disease Can Predict Very Early Outcome After Liver Transplantation
Javier Briceño,J.M. Sánchez-Hidalgo,Álvaro Naranjo,Ruben Ciria,J.C. Pozo,A. Luque,M. de la Mata,S. Rufian,P. López-Cillero +8 more
- 01 Nov 2008
TL;DR: This study corroborated the suggestion that the MELD score may serve as a reliable tool to assess very early death after liver transplantation (OLT), using a time-dependent general linear regression model.
8